An observational study in Malignant Pleural Mesothelioma and Unresectable Malignant Neoplasm, sponsored by Groupe Francais De Pneumo-Cancerologie. Completed at 63 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Groupe Francais De Pneumo-Cancerologie · Observational
Among 29 studies in Mesothelioma, Malignant with a site in France — 7 open to participants now, 10 under way, 1 of them phase 3. Mesothelioma, Malignant · France.
Among the 29 studies in Mesothelioma, Malignant with a site in France, this one is one of 3 that started in 2022, is one of 6 observational ones, and was the 25th registered.
339 studies on the registry are indexed under Mesothelioma, Malignant; 64 are open to participants now.
This study's enrollment of 204 is above the median of 150 across 40 observational studies indexed under Mesothelioma, Malignant.
Browse Mesothelioma, Malignant studies →7 of the 29 studies in Mesothelioma, Malignant with a site in France are open now, in 7 countries. Each count lists the studies.
Of the 55 Mesothelioma, Malignant studies recruiting now, 43 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →29 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2022.
Median enrollment 106 across the 23 interventional studies, 237 across the 6 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
11 of 29 have an industry lead sponsor. The 10 most frequent:
Groupe Francais De Pneumo-Cancerologie is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Groupe Francais De Pneumo-Cancerologie has 1 study filed under Mesothelioma, Malignant — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Mesothelioma, Malignant with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
Meso-Immune is a retrospective study to assess the efficacy and safety of the combination of Nivolumab and Ipilimumab used in first-line treatment of adult patients with unresectable Malignant Pleural Mesothelioma (MPM). This combination of treatments has been approved in Europe since June 2021 based on the results of the CheckMate 743 study. In France, the combination is not yet reimbursed for this population of patients. However, since April 01, 2021, newly diagnosed unresectable MPM patients may be treated with this combination via an early access program.
Meso-Immune study targets these patients included in the early access program with the objective to provide additional results to the CheckMate 743 study and confirm the benefit of using this combination in first-line of treatment in this category of patients.
Total study duration will cover 48 months with an inclusion period of 12 months and a follow-up until 3 years. Patients will be recruited retrospectively starting April 01, 2021 until April 01, 2022.
Meso-Immune study will be proposed to all the GFPC centers that have already included patients in the early access program and other centers wishing to participate, in order to analyze a minimum of 150 patients. The total number of sites is evaluated at around 120.
The principal investigator in each center will identify the patients eligible for the Meso-Immune study and will inform them on the study according to the local regulations.
Patient follow-up will be pursued regularly, in in-patient and out-patient clinics, according to the usual practices of the physicians in each participating center. Reevaluation workups will be pursued according to the practices of each center.
The information related to Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news will be recorded in electronic case-report forms (eCRF).
Qualitative variables will be presented descriptively in the principal analysis.
Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma treated with combination Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of his/her data
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma (MPM) treated with combination of Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of their data
Other: Data collection
Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
This study also gives Nivolumab, Ipilimumab. No intervention listed here names it: that was found by reading the record.
Progression Free Survival assessed locally
Progression free survival as assessed by the investigator, defined as the time from first dose of combination Nivolumab-Ipilimumab to first documentation of disease progression or to death from any cause, whichever came first
Time frame: time from first dose of combination Nivolumab-Ipilimumab to first documentation of disease progression or to death from any cause evaluated through the total duration of the study (up to 48 months)
Potential professional exposure(s)
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. Qualitative parameters will be expressed as numbers, percentages and 95% confidence intervals.
Time frame: At Baseline
Eastern Cooperative Oncology Group performance status (PS)
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. Quantitative parameters will be expressed as means, standard deviations or medians and interquartile ranges.
Time frame: At Baseline
Body weight
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes expressed in kilograms. Quantitative parameters will be expressed as means, standard deviations or medians and interquartile ranges.
Time frame: At Baseline
Body mass index (BMI)
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m 2, resulting from mass in kilograms and height in metres. Quantitative parameters will be expressed as means, standard deviations or medians and interquartile ranges.
Time frame: At Baseline
Smoking status
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. Qualitative parameters will be expressed as numbers, percentages and 95% confidence intervals.
Time frame: At Baseline
Medical history
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. Qualitative parameters will be expressed as numbers, percentages and 95% confidence intervals.
Time frame: At Baseline
Comorbidities
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. Qualitative parameters will be expressed as numbers, percentages and 95% confidence intervals.
Time frame: At Baseline
Past history of cancer or auto-immune disease
Unresectable Malignant Pleural Mesothelioma Patients' characteristics based on data collected from the patient medical notes. Qualitative parameters will be expressed as numbers, percentages and 95% confidence intervals.
Time frame: At Baseline
Overall Survival (OS)
OS defined as the time from first treatment start to death for any cause expressed in months
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of the study (up to 48 months)
Objective Response Rate (ORR)
Objective Response Rate (ORR): best overall response of complete response (CR) or partial response (PR) to a first line of treatment using i-RECIST criteria as assessed locally
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of the study (up to 48 months)
Safety of combination Nivolumab-Ipilimumab
Data on adverse events (AEs) will be collected, and relatedness of these events to the use of drugs associated with this study (where applicable) will be assessed.
Time frame: From first dose of combination Nivolumab-Ipilimumab up to 100 days after the last treatment dose administration, up to 48 months (study duration)
Treatment duration
Time to treatment failure, defined as the time from the first dose of combination Nivolumab-Ipilimumab to disease progression locally assessed, death, non-objection withdrawn, adverse event, lost to follow-up or initiation of another anticancer treatment.
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of treatment, up to 48 months (study duration)
Reasons for treatment discontinuation
Reasons for treatment discontinuation will be collected and recorded in the e-CRF
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of treatment, up to 48 months (study duration)
Post-progression treatments
The name, start and end date, of treatments initiated after the disease progression of the patient will be collected and recorded in the e-CRF. Date of progression for these treatments will be reported as well.
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of the study (up to 48 months)
Treatment outcome in terms of PFS in subgroups of patients according to patient's characteristics: elderly patients (age >80 years old), patients with performance status >1, patients with comorbidities
Treatment outcome in terms of progression free survival as assessed by the investigator, defined as the time from first dose of combination Nivolumab-Ipilimumab to first documentation of disease progression or to death from any cause, whichever came first
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of the study (up to 48 months)
Treatment outcomes in terms of AEs in subgroups of patients according to patient's characteristics: elderly patients (age >80 years old), patients with performance status >1, patients with comorbidities
Treatment outcome in terms of proportion (%) of patients with any adverse event (AE) and number and severity of events per subgroup of patients
Time frame: From first dose of combination Nivolumab-Ipilimumab to the end of the study (up to 48 months)
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Aug 2025, 39 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe Francais De Pneumo-Cancerologie